rhBMP-2/Calcium Phosphate Matrix Induces Bone Formation While Limiting Transient Bone Resorption in a Nonhuman Primate Core Defect Model

被引:11
|
作者
Seeherman, Howard J. [1 ]
Li, X. Jian [1 ]
Smith, Erica [1 ]
Wozney, John M. [1 ]
机构
[1] Pfizer Discovery Res, Inflammat & Remodeling, Cambridge, MA 02140 USA
来源
关键词
OSTEOBLAST LINEAGE CELLS; MORPHOGENETIC PROTEIN-2; OSTEOCLAST FORMATION; OSTEOTOMY; CEMENT; OP-1; OSTEOPROTEGERIN; IMPLANTS; INGROWTH;
D O I
10.2106/JBJS.K.00523
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Transient bone resorption limits the use of recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge in metaphyseal bone. The purpose of the present study was to evaluate the efficacy of rhBMP-2/calcium phosphate matrix (CPM) to induce bone formation while limiting transient bone resorption in nonhuman primate core defects. Methods: Metaphyseal core defects were created in eighteen cynomolgus monkeys. rhBMP-2 retention was evaluated in the distal part of the radius. Bone formation was evaluated at eight weeks following treatment with 1.5 or 4.5-mg/mL rhBMP-2/CPM, CPM alone, or no treatment in the distal part of the radius, the proximal part of the tibia, and the proximal part of the femur; at twenty-four weeks following treatment with 1.5-mg/mL rhBMP-2/CPM or CPM alone in the proximal part of the tibia; and at one, two, and four weeks following treatment with 1.5-mg/mL rhBMP-2/CPM or no treatment in the distal part of the radius. Bone resorption was evaluated at four weeks following treatment with 1.5, 2.0, 3.0, and 4.5-mg/mL rhBMP-2/CPM or CPM alone in the distal part of the femur. Evaluations were performed with use of scintigraphy, radiographs, histological analysis, and computed tomography. Results: Seventy-eight percent, 64%, 50%, 35%, and 12% of the rhBMP-2 was retained in the distal part of the radius at one, seven, fourteen, twenty-one, and forty-nine days after surgery. rhBMP-2/CPM increased bone formation within core defects and surrounding trabeculae compared with CPM alone or no treatment at all anatomic locations at eight weeks, and bone formation was ongoing in the rhBMP-2/CPM-treated proximal tibial sites at twenty-four weeks. Bone formation began in the trabeculae surrounding the core defects at one week and was observed adjacent to the resorbing CPM within the core defects and in the surrounding trabecular bone at two and four weeks in the rhBMP-2/CPM-treated distal radial sites. Bone formation was confined to the region immediately surrounding the core defects in the untreated distal radial sites at all time points. Transient bone resorption was only observed in the distal femoral sites treated with 4.5 mg/mL of rhBMP-2/CPM at two weeks. Conclusions: Treatment of nonhuman primate metaphyseal core defects with 1.5 to 3.0-mg/mL rhBMP-2/CPM resulted in bone formation without transient bone resorption.
引用
收藏
页码:1765 / 1776
页数:12
相关论文
共 50 条
  • [1] rhBMP-2 Induces Transient Bone Resorption Followed by Bone Formation in a Nonhuman Primate Core-Defect Model
    Seeherman, Howard J.
    Li, X. Jian
    Bouxsein, Mary L.
    Wozney, John M.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2010, 92A (02): : 411 - 426
  • [2] RhBMP-2/ACS stimulates bone resorption prior to bone formation in nonhuman primate core defects
    Seeherman, HJ
    Li, XJ
    Blake, C
    Wozney, JM
    Bouxsein, ML
    BONE, 2002, 30 (03) : 21S - 21S
  • [3] Bisphosphonate limits initial bone resorption without decreasing bone induction in rhBMP-2/ACS treated nonhuman primate core defects
    Seeherman, HJ
    Li, XJ
    Gavin, D
    Wozney, JM
    Bouxsein, ML
    BONE, 2002, 30 (03) : 44S - 44S
  • [4] Histology indicates bisphosphonate limits transient resorption without decreasing subsequent bone induction in nonhuman primate core defects treated with rhBMP-2/ACS.
    Seeherman, HJ
    Li, X
    Blake, C
    Gavin, D
    Wozney, JM
    Bouxsein, ML
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S438 - S438
  • [5] rhBMP-2/CPM accelerates metaphyseal trabecular bone formation in a non-human primate core defect model.
    Li, X
    Gavin, D
    Wallace, C
    Li, L
    Wozney, JM
    Seeherman, HJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S209 - S209
  • [6] Effect Of Beta-tricalcium Phosphate Ceramics With Rhbmp-2 for Bone Formation in Canine Alveolar Bone Defect Model
    Hwang, S.
    Cho, T.
    Kim, I.
    Kim, N.
    TISSUE ENGINEERING PART A, 2015, 21 : S332 - S332
  • [7] ECTOPIC BONE-FORMATION BY RHBMP-2 WITH VARIOUS CALCIUM-PHOSPHATE CERAMICS
    ODA, S
    KINOSHITA, A
    HIGUCHI, T
    ISHIKAWA, I
    JOURNAL OF DENTAL RESEARCH, 1995, 74 : 574 - 574
  • [8] rhBMP-2/calcium phosphate matrix accelerates osteotomy-site healing in a nonhuman primate model at multiple treatment times and concentrations
    Seeherman, H
    Li, R
    Bouxsein, M
    Kim, H
    Li, XJ
    Smith-Adaline, EA
    Aiolova, M
    Wozney, JM
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2006, 88A (01): : 144 - 160
  • [9] Intraosseous Injection of rhBMP-2/Calcium Phosphate Matrix Improves Bone Structure and Strength in the Proximal Aspect of the Femur in Chronic Ovariectomized Nonhuman Primates
    Seeherman, Howard J.
    Li, X. Jian
    Smith, Erica
    Parkington, Jascha
    Li, Rebecca
    Wozney, John M.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2013, 95A (01): : 36 - 47
  • [10] Combination treatment of rhBMP-2 and bisphosphonate stimulate bone formation and inhibit bone resorption in the transplanted bone allograft.
    Kaji, Y
    Mori, S
    Mashiba, T
    Manabe, T
    Akiyama, T
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S321 - S321